Atenolol Pathway


Atenolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles.

Pathway legend Zoom in Zoom out

Pathway Image

Pathway legend Zoom in Zoom out

References

  1. Borchard, U. (1998). Pharmacological properties of beta-adrenoceptor blocking drugs. Journal of Clinical and Basic Cardiology, 1(1), 5-9.
  2. DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G, & Posey, M.L. (2005). Pharmacotherapy: A pathologic approach. (6 th ed) pp.207-208. New York: McGraw-Hill Medical Publishing Division.
  3. Tenormin. (2009). [Electronic version]. e-CPS. Retrieved July 25, 2009.